• 1
    Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol Mech Dis 2006; 1: 23-61.
  • 2
    Rehermann B. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis 2007; 27: 152-160.
  • 3
    Yewdell JW, Bennink JR. Mechanisms of viral interference with MHC class I antigen processing and presentation. Annu Rev Cell Dev Biol 1999; 15: 579-606.
  • 4
    Bruss V. Envelopment of the hepatitis B virus nucleocapsid. Virus Res 2004; 106: 199-209.
  • 5
    Simsek E, Mehta A, Zhou T, Dwek RA, Block T. Hepatitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme. J Virol 2005; 79: 12914-12920.
  • 6
    Block TM, Mehta AS, Blumberg BS, Dwek RA. Does rapid oligomerization of hepatitis B envelope proteins play a role in resistance to proteasome degradation and enhance chronicity? DNA Cell Biol 2006; 25: 165-170.
  • 7
    Mehta A, Lu X, Block TM, Blumberg BS, Dwek RA. Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. Proc Natl Acad Sci U S A 1997; 94: 1822-1827.
  • 8
    Werr M, Prange R. Role for calnexin and N-linked glycosylation in the assembly and secretion of hepatitis B virus middle envelope protein particles. J Virol 1998; 72: 778-782.
  • 9
    Bergeron JJ, Brenner MB, Thomas DY, Williams DB. Calnexin: a membrane-bound chaperone of the endoplasmic reticulum. Trends Biochem Sci 1994; 19: 124-128.
  • 10
    Parodi AJ. Protein glucosylation and its role in protein folding. Ann Rev Biochem 2000; 69: 69-93.
  • 11
    Block TM, Lu X, Mehta A, Blumberg BS, Tennant B, Ebling M, et al. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nature Med 1998; 4: 610-614.
  • 12
    Liu Y, Simsek E, Norton P, Sinnathamby G, Philip R, Block T, et al. The role of the downstream signal sequences in the maturation of the HBV middle surface glycoprotein: development of a novel therapeutic vaccine candidate. Virology 2007; 365: 10-19.
  • 13
    Simsek E, Sinnathamby G, Block TM, Liu Y, Philip R, Mehta AS, et al. Inhibition of cellular alpha-glucosidases results in increased presentation of hepatitis B virus glycoprotein-derived peptides by MHC class I. Virology 2009; 384: 12-15.
  • 14
    Suzuki T, Seko A, Kitajima K, Inoue Y, Inoue S. Purification and enzymatic properties of peptide:N-glycanase from C3H mouse-derived L-929 fibroblast cells. Possible widespread occurrence of post-translational remodification of proteins by N-deglycosylation. J Biol Chem 1994; 269: 17611-17618.
  • 15
    Suzuki T, Lennarz W. Hypothesis: a glycoprotein-degradation complex formed by protein-protein interaction involves cytosolic peptide:N-glycanase. Biochem Biophys Res Commun 2003; 302: 1-5.
  • 16
    Wiertz E, Jones T, Sun L, Bogyo M, Geuze H, Ploegh H. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 1996; 84: 769-779.
  • 17
    Altrich-VanLith M, Ostankovitch M, Polefrone J, Mosse C, Shabanowitz J, Hunt D, et al. Processing of a class I-restricted epitope from tyrosinase requires peptide N-glycanse and the cooperative action of endoplasmic reticulum aminopeptidase 1 and clytosolic proteases. J Immunol 2006; 177: 5440-5450.
  • 18
    Hudrisier D, Riondi J, Mazarguil H, Gairin JE. Pleiotropic effects of post-translational modifications on the fate of viral glycoproteins a cytotoxic T cell epitopes. J Biol Chem 2001; 276: 38255-38260.
  • 19
    Selby M, Erickson A, Dong C, Cooper S, Parham P, Houghton M, et al. Hepatitis C virus envelope glycoprotein E1 originates in the endoplasmic reticulum and requires cytoplasmic processing for presentation by class I MHC molecules. J Immunol 1999; 162: 669-676.
  • 20
    Menne S, Cote P. The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol 2007; 13: 104-124.
  • 21
    Sinnathamby G, Lauer P, Zerfass J, Hanson B, Karabudak A, Krakover J, et al. Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines. J Immunother 2009; 32: 856-869.
  • 22
    Sells MA, Chen ML, Acs G. Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A 1987; 84: 1005-1009.
  • 23
    Cote PJ, Korba BE, Miller RH, Jacob JR, Baldwin BH, Hornbuckle WE, et al. Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection. HEPATOLOGY 2000; 31: 190-200.
  • 24
    Gerin J, Faust R, Holland P. Biophysical characterization of the adr subtype of hepatitis B antigen and preparation of anti-r sera in rabbits. J Immunol 1975; 115: 100-105.
  • 25
    Menne S, Cote PJ, Butler SD, George AL, Tochkov IA, Zhu Y, et al. Antiviral effect of orally administered lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate, alone and in combination in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother 2008; 52: 3617-3632.
  • 26
    Cote PJ, Roneker C, Cass K, Schodel F, Peterson D, Tennant BC, et al. New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection. Viral Immunol 1993; 6: 161-169.
  • 27
    Comunale MA, Lowman M, Long RE, Krakover J, Philip R, Seeholzer S, et al. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res 2006; 6: 308-315.
  • 28
    Royle L, Mattu TS, Hart E, Langridge JI, Merry AH, Murphy N, et al. An analytical and structural database provides a strategy for sequencing O-glycans from microgram quantities of glycoproteins. Anal Biochem 2002; 304: 70-90.
  • 29
    Menne S, Roneker CA, Tennant BC, Korba BE, Gerin JL, Cote PJ. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J Virol 2002; 76: 5305-5314.
  • 30
    Menne S, Tennant BC, Gerin JL, Cote PJ. Chemoimmunotherapy of chronic hepatitis B virus infection in the woodchuck model overcomes immunologic tolerance and restores T-cell responses to pre-S and S regions of the viral envelope protein. J Virol 2007; 81: 10614-10624.
  • 31
    Menne S, Roneker CA, Roggendorf M, Gerin JL, Cote PJ, Tennant BC. Deficiencies in the acute-phase cell-mediated immune response to viral antigens are associated with development of chronic woodchuck hepatitis virus infection following neonatal inoculation. J Virol 2002; 76: 1769-1780.
  • 32
    Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60.
  • 33
    Ito Y, Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Koike K. Cytotoxic T lymphocyte activity to hepatitis B virus DNA-transfected HepG2 cells in patients with chronic hepatitis B. Gastroenterol Jpn 1993; 28: 657-665.
  • 34
    Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanović S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-219.
  • 35
    Menne S, Roneker CA, Tennant BC, Korba BE, Gerin JL, Cote PJ. Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology 2002; 45: 237-250.
  • 36
    Gross V, Tran-Thi TA, Schwarz RT, Elbein AD, Decker K, Heinrich PC. Different effects of the glucosidase inhibitors 1-deoxynojirimycin, N-methyl-1-deoxynojirimycin and castanospermine on the glycosylation of rat alpha 1-proteinase inhibitor and alpha 1-acid glycoprotein. Biochem J 1986; 236: 853-860.
  • 37
    Kaushal GP, Pan YT, Tropea JE, Mitchell M, Liu P, Elbein AD. Selective inhibition of glycoprotein-processing enzymes. Differential inhibition of glucosidases I and II in cell culture. J Biol Chem 1988; 263: 17278-17283.
  • 38
    Taylor DL, Kang MS, Brennan TM, Bridges CG, Sunkara PS, Tyms AS. Inhibition of alpha-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoyl castanospermine (MDL 28,574) and its consequences in human immunodeficiency virus-infected T cells. Antimicrob Agents Chemother 1994; 38: 1780-1787.
  • 39
    Moore SEH, Spiro RG. Demonstration that golgi endo-a-D-mannosidase provides a glucosidase-independent pathway for the formation of complex N-linked oligosaccharides of glycoproteins. J Biol Chem 1990; 265: 13104-13112.
  • 40
    Heathcote J, McHutchinson J, Lee S, Tong M, Benner K, Minuk G, et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. HEPATOLOGY 1999; 30: 531-536.
  • 41
    Mitchell MS. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope (in reply). J Clin Oncol 2002; 20: 3176-3184.
  • 42
    Moore SE, Spiro RG. Inhibition of glucose trimming by castanospermine results in rapid degradation of unassembled major histocompatibilty complex class I molecules. J Biol Chem 1993; 268: 3809-3812.
  • 43
    Wang J, Michalak TI. Inhibition by woodchuck hepatitis virus of class I major histocompatibility complex presentation on hepatocytes is mediated by virus envelope pre-S2 protein and can be reversed by treatment with gamma interferon. J Virol 2006; 80: 8541-8553.